Armata Pharmaceuticals, Inc. – AMEX:ARMP

Add to watchlist

$2.54

+0.43

+20.38%

Market closed

Open in about 8 hours

-33.02%

month

-33.02%

quarter

-14.68%

year

Market Cap	67.30M
Enterprise value	87.30M

P/E	-1.31
EV/Sales	N/A
EV/EBITDA	-2.42
Price/Sales	N/A
Price/Book	1.47
PEG ratio	0.10
EPS	-2.19

Revenue	4.69M
EBITDA	-60.76M
Income	-79.57M
Revenue Q/Q	21.35%
Revenue Y/Y	-7.28%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-1293.1%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Profit margin
Jun 2023	980K	-3.54M	-361.94%
Sep 2023	1.22M	-31.16M	-2543.76%
Dec 2023	1.52M	-19.84M	-1298.89%
Mar 2024	966K	-25.02M	-2590.17%

Armata Pharmaceuticals Financials Estimate

Q Y

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Analyst Estimates
Mar 2024	966K	-25.02M	-2590.17%
Sep 2025	2.30M	-10.83M	-470.82%
Oct 2025	1.37M	-7.22M	-526.72%
Dec 2025	1.45M	-10.47M	-720.39%

Analysts Price target
Financials & Ratios estimates

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Earnings per share (EPS)
2023-11-14	-0.33	-0.31

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Debt to assets
Jun 2023	101212000	82.06M	81.09%
Sep 2023	112761000	125.14M	110.98%
Dec 2023	109964000	142.02M	129.16%
Mar 2024	120356000	176.86M	146.95%

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Cash Flow
Jun 2023	-12.06M	-222K	-368K
Sep 2023	-9.68M	-3.51M	24.80M
Dec 2023	-8.10M	-2.39M	-43K
Mar 2024	-10.58M	-250K	34.93M

Armata Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Armata Pharmaceuticals
Employees

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Employee count
Aug 2023	72
Sep 2023	72
Oct 2023	72
Nov 2023	72
Dec 2023	72
Jan 2024	72
Feb 2024	72
Mar 2024	66
Apr 2024	66
May 2024	66
Jun 2024	66
Jul 2024	66

Armata Pharmaceuticals
Hedge Funds Holdings Q1 2023

2.67% -0.94%

of ARMP is owned by hedge funds

13 -12

hedge funds hold ARMP stock

916.42K -386.90K

shares is hold by hedge funds

ARMP hedge funds holdings changes

Armata Pharmaceuticals
Insider Trading

Armata Pharmaceuticals, Inc. (AMEX:ARMP): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	5422188	0
Mar 2022	5385208	0
Jan 2023	0	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	10 Jan 2023	INNOVIVA, INC. director director	Convertible Debt convertible into Common Stock	0	$30,000,000	$0
Purchase	31 Mar 2022	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Warrants to Purchase Common Stock	0	$5	$0
Purchase	31 Mar 2022	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	5,385,208	$5	$26,926,040
Purchase	9 Feb 2022	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Warrants to Purchase Common Stock	1,807,396	$5	$9,036,980
Purchase	9 Feb 2022	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	3,614,792	$5	$18,073,960
Purchase	29 Oct 2021	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	1,212,122	$3.3	$4,000,003
Purchase	17 Mar 2021	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	4,285,935	N/A	N/A
Purchase	26 Jan 2021	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	1,867,912	N/A	N/A
Purchase	27 Mar 2020	INNOVIVA, INC. director, 10 percent owner director, 10 percent owner	Common Stock	7,717,661	N/A	N/A
Purchase	22 Mar 2018	PERRY MICHAEL S director director	Common Stock	181,820	N/A	N/A

ARMP insider trading transactions

Armata Pharmaceuticals
Patents

Status	Patent	Filling date	Issue date
Application	Application BACTERIOPHAGE FOR TREATMENT AND PREVENTION OF BACTERIA-ASSOCIATED CANCERS Filling date: 7 Feb 2019 Issue date: 2 Dec 2021	7 Feb 2019	2 Dec 2021
Application	Application BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONS Filling date: 2 Jan 2019 Issue date: 25 Nov 2021	2 Jan 2019	25 Nov 2021
Application	Application BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION Filling date: 27 Apr 2021 Issue date: 28 Oct 2021	27 Apr 2021	28 Oct 2021
Application	Application BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION Filling date: 18 Feb 2021 Issue date: 19 Aug 2021	18 Feb 2021	19 Aug 2021
Application	Application THERAPEUTIC BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION Filling date: 2 Jan 2019 Issue date: 18 Mar 2021	2 Jan 2019	18 Mar 2021
Application	Application THERAPEUTIC BACTERIOPHAGE COMPOSITIONS Filling date: 27 Dec 2019 Issue date: 4 Jun 2020	27 Dec 2019	4 Jun 2020
Application	Application THERAPEUTIC BACTERIOPHAGE COMPOSITIONS Filling date: 13 Feb 2017 Issue date: 28 Nov 2019	13 Feb 2017	28 Nov 2019

ARMP patents

Armata Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2018 16 May 2018	Q1 2018 Earnings Call Transcript
Q3 2017 15 Nov 2017	Q3 2017 Earnings Call Transcript
Q2 2017 15 Aug 2017	Q2 2017 Earnings Call Transcript
Q1 2017 15 May 2017	Q1 2017 Earnings Call Transcript

ARMP earnings call transcripts

Armata Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Todd R. Patrick MBA (1963) Advisor & Director	62	$773,250
Dr. Brian Varnum Ph.D. (1960) Chief Executive Officer & Director	65	$558,250
Mr. Steven R. Martin (1961) Chief Financial Officer	64	$490,000

Armata Pharmaceuticals
Latest News

Thursday, 19 December 2024
07:00	Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	prnewswire.com
Tuesday, 19 November 2024
07:00	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting	prnewswire.com
Wednesday, 13 November 2024
18:20	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:05	Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update	prnewswire.com
Tuesday, 12 November 2024
07:00	Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia	prnewswire.com
Wednesday, 30 October 2024
07:00	Armata Pharmaceuticals Announces Structural Biology Publication	prnewswire.com
Thursday, 12 September 2024
13:00	Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Thursday, 5 September 2024
07:30	Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference	prnewswire.com
Monday, 26 August 2024
07:30	Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium	prnewswire.com
Thursday, 15 August 2024
16:45	Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer	prnewswire.com
Tuesday, 13 August 2024
16:05	Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update	prnewswire.com
Tuesday, 30 July 2024
07:00	Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02	prnewswire.com
Thursday, 11 July 2024
07:00	Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	prnewswire.com
Wednesday, 10 July 2024
16:05	Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024	prnewswire.com
Tuesday, 7 May 2024
16:01	Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update	prnewswire.com
Thursday, 21 March 2024
16:05	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update	prnewswire.com
Monday, 4 March 2024
16:01	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva	prnewswire.com
Wednesday, 21 February 2024
07:00	Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit	prnewswire.com
Tuesday, 14 November 2023
16:00	Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update	prnewswire.com
Monday, 30 October 2023
08:00	Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	prnewswire.com
Thursday, 19 October 2023
08:00	Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023	prnewswire.com
Tuesday, 22 August 2023
12:02	Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why	Zacks Investment Research
Thursday, 11 May 2023
19:02	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 28 November 2022
11:17	After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)	Zacks Investment Research
08:00	Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage	PRNewsWire
Wednesday, 9 November 2022
20:19	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Thursday, 11 August 2022
18:49	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research
Thursday, 12 May 2022
19:34	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Thursday, 17 February 2022
08:00	Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences	PRNewsWire
Thursday, 6 January 2022
09:59	Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 9 Oct 2023

Innoviva: A Lot Of Moving Parts
Seeking Alpha 9 Oct 2021

The Best Of Backtesting - Week Oct. 4
Seeking Alpha 6 Oct 2021

BiomX: Undervalued With Multiple Upcoming Catalysts

Frequently Asked Questions (FAQ)

What's the price of Armata Pharmaceuticals stock today?

One share of Armata Pharmaceuticals stock can currently be purchased for approximately $2.54.
When is Armata Pharmaceuticals's next earnings date?

Unfortunately, Armata Pharmaceuticals's (ARMP) next earnings date is currently unknown.
Does Armata Pharmaceuticals pay dividends?

No, Armata Pharmaceuticals does not pay dividends.
How much money does Armata Pharmaceuticals make?

Armata Pharmaceuticals has a market capitalization of 67.30M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 17.77% to 4.53M US dollars. Armata Pharmaceuticals made a loss 69.05M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
What is Armata Pharmaceuticals's stock symbol?

Armata Pharmaceuticals, Inc. is traded on the AMEX under the ticker symbol "ARMP".
What is Armata Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Armata Pharmaceuticals?

Shares of Armata Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Armata Pharmaceuticals's key executives?
Armata Pharmaceuticals's management team includes the following people:
- Mr. Todd R. Patrick MBA Advisor & Director(age: 62, pay: $773,250)
- Dr. Brian Varnum Ph.D. Chief Executive Officer & Director(age: 65, pay: $558,250)
- Mr. Steven R. Martin Chief Financial Officer(age: 64, pay: $490,000)
How many employees does Armata Pharmaceuticals have?

As Jul 2024, Armata Pharmaceuticals employs 66 workers.
When Armata Pharmaceuticals went public?

Armata Pharmaceuticals, Inc. is publicly traded company for more then 31 years since IPO on 20 May 1994.
What is Armata Pharmaceuticals's official website?

The official website for Armata Pharmaceuticals is armatapharma.com.
Where are Armata Pharmaceuticals's headquarters?

Armata Pharmaceuticals is headquartered at 4503 Glencoe Avenue, Marina del Rey, CA.
How can i contact Armata Pharmaceuticals?

Armata Pharmaceuticals's mailing address is 4503 Glencoe Avenue, Marina del Rey, CA and company can be reached via phone at 858 829 0829.

Armata Pharmaceuticals, Inc.

armatapharma.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

858 829 0829

4503 Glencoe Avenue
Marina del Rey, CA 90292

CIK: 0000921114
ISIN: US04216R1023
CUSIP: 04216R102